Cargando…
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
BACKGROUND: Atezolizumab plus bevacizumab has been proved to have promising antitumor activity and tolerable safety in patients with unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) also demonstrated high response rates and favorable survival for patients wi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388744/ https://www.ncbi.nlm.nih.gov/pubmed/35990634 http://dx.doi.org/10.3389/fimmu.2022.929141 |
_version_ | 1784770278882017280 |
---|---|
author | Xin, Yujing Cao, Fei Yang, Hongcai Zhang, Xinyuan Chen, Yi Cao, Xiaojing Zhou, Xiang Li, Xiao Zhou, Jinxue |
author_facet | Xin, Yujing Cao, Fei Yang, Hongcai Zhang, Xinyuan Chen, Yi Cao, Xiaojing Zhou, Xiang Li, Xiao Zhou, Jinxue |
author_sort | Xin, Yujing |
collection | PubMed |
description | BACKGROUND: Atezolizumab plus bevacizumab has been proved to have promising antitumor activity and tolerable safety in patients with unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) also demonstrated high response rates and favorable survival for patients with advanced HCC. This study aimed to explore the preliminary clinical efficacy and safety of atezolizumab plus bevacizumab combined with HAIC for patients with treatment-naive advanced HCC. METHODS: Between October 2020 and September 2021, patients with advanced HCC who initially received atezolizumab plus bevacizumab combined with HAIC of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) from three hospitals in China were reviewed for eligibility. The efficacy was evaluated by tumor response rate and survival, and the safety was evaluated by the frequency of key adverse events (AEs). RESULTS: In total, 52 eligible patients with advanced HCC who received triple therapy were included in this study. The objective response rates (ORRs) based on mRECIST and RECIST1.1 criteria were 67.3% and 44.2%, respectively. The median progression-free survival (PFS) of patients was 10.6 months (95% CI, 8.37–13.8), and the overall survival (OS) was not reached. Extrahepatic metastasis was an independent risk factor associated with PFS. All AEs were controlled and no treatment-related deaths occurred. CONCLUSION: Atezolizumab plus bevacizumab combined with HAIC-FOLFOX had a significant therapeutic effect and manageable AEs in patients with advanced HCC, which may be a potential treatment option for advanced HCC. |
format | Online Article Text |
id | pubmed-9388744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93887442022-08-20 Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma Xin, Yujing Cao, Fei Yang, Hongcai Zhang, Xinyuan Chen, Yi Cao, Xiaojing Zhou, Xiang Li, Xiao Zhou, Jinxue Front Immunol Immunology BACKGROUND: Atezolizumab plus bevacizumab has been proved to have promising antitumor activity and tolerable safety in patients with unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) also demonstrated high response rates and favorable survival for patients with advanced HCC. This study aimed to explore the preliminary clinical efficacy and safety of atezolizumab plus bevacizumab combined with HAIC for patients with treatment-naive advanced HCC. METHODS: Between October 2020 and September 2021, patients with advanced HCC who initially received atezolizumab plus bevacizumab combined with HAIC of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) from three hospitals in China were reviewed for eligibility. The efficacy was evaluated by tumor response rate and survival, and the safety was evaluated by the frequency of key adverse events (AEs). RESULTS: In total, 52 eligible patients with advanced HCC who received triple therapy were included in this study. The objective response rates (ORRs) based on mRECIST and RECIST1.1 criteria were 67.3% and 44.2%, respectively. The median progression-free survival (PFS) of patients was 10.6 months (95% CI, 8.37–13.8), and the overall survival (OS) was not reached. Extrahepatic metastasis was an independent risk factor associated with PFS. All AEs were controlled and no treatment-related deaths occurred. CONCLUSION: Atezolizumab plus bevacizumab combined with HAIC-FOLFOX had a significant therapeutic effect and manageable AEs in patients with advanced HCC, which may be a potential treatment option for advanced HCC. Frontiers Media S.A. 2022-08-05 /pmc/articles/PMC9388744/ /pubmed/35990634 http://dx.doi.org/10.3389/fimmu.2022.929141 Text en Copyright © 2022 Xin, Cao, Yang, Zhang, Chen, Cao, Zhou, Li and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xin, Yujing Cao, Fei Yang, Hongcai Zhang, Xinyuan Chen, Yi Cao, Xiaojing Zhou, Xiang Li, Xiao Zhou, Jinxue Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
title | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
title_full | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
title_fullStr | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
title_full_unstemmed | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
title_short | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
title_sort | efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388744/ https://www.ncbi.nlm.nih.gov/pubmed/35990634 http://dx.doi.org/10.3389/fimmu.2022.929141 |
work_keys_str_mv | AT xinyujing efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT caofei efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT yanghongcai efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT zhangxinyuan efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT chenyi efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT caoxiaojing efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT zhouxiang efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT lixiao efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT zhoujinxue efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma |